Laura Harris: Unfiltered

With a fresh $31M, Advanced NanoTherapies is advancing a first-of-its-kind dual-drug nanoparticle balloon, a technology poised to disrupt the market.

Neil Jesani Advisors' high-profile board appointments reveal a new playbook for growth, where political savvy and tech innovation are the ultimate currency.

The FDA just granted Orphan Drug status to a promising ALS therapy. It's a beacon of hope for patients and a masterclass in biotech strategy.

A John Oliver segment exposed an industry preying on injury victims. Now, a proven Maryland law offers a nationwide blueprint for consumer protection.

A new device from Stelar and HTS-110 shrinks a room-sized instrument onto a lab bench, set to accelerate breakthroughs in medicine, batteries, and more.

With Jackie Chan as its face, Trip.com Group is betting big on Guilin to attract a new wave of global tourists. But can this push for 'authentic' slow travel survive its own celebrity-fueled success?

Facing a severe cash crunch, Jasper Therapeutics is exploring a sale or even a shutdown, placing the future of its promising urticaria drug, briquilimab, in limbo.

Canada Post unveils its final 'Places of Pride' stamps, honouring four historic sites that were crucial in the fight for equality and community.

Biotech firm Kimera Labs implements a unified quality system for its exosome therapies and cosmetics, raising the bar in a complex regulatory landscape.

A landmark 160MWh battery project in Romania debuts Trina's advanced integrated solution, signaling a new era for grid stability in Southeast Europe.

Ardoq's new AI-first platform reasons on live, governed data, aiming to automate routine tasks and solve the trust problem plaguing enterprise AI.

A Tulsa jury found a doctor negligent, awarding $15M to a girl left with severe brain damage after a missed diagnosis of bacterial meningitis as an infant.

With backing from GV and Dexcom, Signos is using AI and OTC glucose monitors to offer a new path for sustainable weight management beyond GLP-1 drugs.

Anza launches Pulse, an on-demand intelligence platform aiming to replace outdated reports with live pricing and policy insights for a volatile solar market.

After a 90% value drop and dividend halt at a BDC, an activist investor calls out manager Investcorp for broken promises and excessive fees.

As CEO Mike Mazzei preps for Nareit’s REITweek, investors seek clues on BrightSpire's growth plan and dividend health in a shifting CRE market.

Author Doreszell Cohen-Bakam's new book 'OUT' critiques a broken system and calls for a new generation of leaders to save democracy from the outside.

As AI's energy thirst drives a nuclear power revival, System One hires key experts to tackle small modular reactors, plant restarts, and spent fuel.

A new analysis reveals most insured Americans can't access obesity drugs, even with coverage, due to restrictive insurance hurdles.

Dstny Group appoints a new Chief Customer Officer, signaling a strategic bet on superior customer experience to fuel its aggressive European expansion.